...
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >A multiple ascending dose study of CSL112, an infused formulation of ApoA-I
【24h】

A multiple ascending dose study of CSL112, an infused formulation of ApoA-I

机译:CSL112的多个上升剂量研究,一种注入Apoa-i的制剂

获取原文
获取原文并翻译 | 示例
           

摘要

CSL112 is apoA-I purified from human plasma and reconstituted with phosphatidylcholine (PC) to form high-density lipoprotein (HDL)-particles suitable for infusion. CSL112 is in development for the potential treatment of acute coronary syndromes (ACS) by optimizing cholesterol efflux. This study assesses the pharmacokinetics (PK), safety and tolerability of CSL112. Repeat doses of CSL112 or placebo were administered intravenously once- (3.4 g or 6.8 g) or twice-weekly (3.4 g) to healthy subjects in a placebo-controlled, randomized (3 CSL112: 1 placebo), ascending-dose study (NCT01281774). Twenty-seven subjects received CSL112 and nine received placebo. Study endpoints included plasma apoA-I and PC concentrations and specific PK parameters. CSL112 infusions immediately produced robust increases in apoA-I concentration in a dose-proportional manner, reaching levels higher than observed with currently available or investigational HDL products. After infusion of CSL112, apoA-I levels remained above baseline for approximately 3 days. Multiple infusions of CSL112 were safe and well tolerated with no evidence of major organ toxicity or immunogenicity. CSL112 may provide a novel option to rapidly transport cholesterol from atherosclerotic plaque to the liver and reduce early recurrent events following ACS. The data presented here support continued clinical development of CSL112 in patient populations.
机译:CSL112是从人血浆中纯化的APOA-I,并用磷脂酰胆碱(PC)重构以形成适合输注的高密度脂蛋白(HDL)颗粒。 CSL112正在开发通过优化胆固醇流出来潜在治疗急性冠状动脉综合征(ACS)。该研究评估了CSL112的药代动力学(PK),安全性和耐受性。将CSL112或安慰剂的重复剂量静脉内 - (3.4g或6.8g)或两次(3.4g)给予安慰剂,随机(3个CSL112:1安慰剂),上升剂量研究(NCT01281774 )。二十七名受试者收到CSL112和9​​个接受的安慰剂。研究终点包括等离子体apoa-1和PC浓度和特定的PK参数。 CSL112输注立即产生apoa-i浓度的稳健增加以剂量比例的方式,达到比目前可用的或调查的HDL产品高的水平高。输注CSL112后,ApoA-1水平仍然高于基线约3天。 CSL112的多次输注是安全且耐受性的,没有主要器官毒性或免疫原性的证据。 CSL112可以提供一种新颖的选择,可以将胆固醇快速转运胆固醇从动脉粥样硬化斑块到肝脏,并在ACS后降低早期复发事件。这里提出的数据支持患者群体中CSL112的持续临床开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号